Hutchison China MediTech Limited Announces Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

LONDON–(BUSINESS WIRE)–Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces
the closing of its U.S. public offering of American depositary shares
(“ADSs”) (the “Offering”). The Offering raised gross proceeds of
US$101,250,000, through the sale of 7,500,000 ADSs, each representing
one-half of one ordinary share of Chi-Med, at a price of US$13.50 per
ADS. All of the ADSs in the Offering were sold by Chi-Med.

Chi-Med has also granted the underwriters a 30-day option to purchase up
to an additional 1,125,000 ADSs at the Offering price.

The ADSs sold in the Offering began trading on the Nasdaq Global Select
Market on March 17, 2016. Chi-Med’s ordinary shares continue to be
traded on the AIM market of the London Stock Exchange.

BofA Merrill Lynch and Deutsche Bank Securities (in alphabetical order)
acted as joint global coordinators and joint bookrunners for the
Offering. Stifel, Canaccord Genuity, Panmure Gordon & Co. and CITIC CLSA
acted as co-managers for the Offering.

In connection with the Offering, a registration statement on Form F-1
(the “Form F-1 Registration Statement”) has been filed with, and
declared effective by, the U.S. Securities and Exchange Commission
(“SEC”). The Offering was made only by means of a prospectus. Copies of
the final prospectus related to the Offering may be accessed through the
SEC’s website at www.sec.gov
or obtained from (in alphabetical order): (i) BofA Merrill Lynch, Attn:
Prospectus Department, 222 Broadway, New York, NY 10038, or by email at dg.prospectus_requests@baml.com,
or (ii) Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall
Street, New York, NY 10005, or by email at prospectus.cpdg@db.com.

This announcement does not constitute an offer to sell or the
solicitation of an offer to buy ADSs or any other securities, nor shall
there be any sale of ADSs in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

Application has been made for the 3,750,000 new ordinary shares issued
by Chi-Med pursuant to the Offering, represented by the 7,500,000 ADSs,
to be admitted to trading on AIM and it is expected that admission will
become effective at 8.00am (GMT) on March 23, 2016. The 3,750,000 new
ordinary shares issued by Chi-Med pursuant to the Offering have been
credited as fully paid and rank pari passu in all respects with the
existing ordinary shares of Chi-Med. As of the closing of the Offering,
the issued share capital of Chi-Med is 60,283,118 and this figure may be
used by shareholders as a denominator for the calculations by which they
determine if they are required to notify their interest in, or change to
their interest in, Chi-Med under the Disclosure and Transparency Rules,
as incorporated into Chi-Med’s articles of association.

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which
researches, develops, manufactures and sells pharmaceuticals and
health-related consumer products. Its Innovation Platform focuses on
discovering and developing innovative therapeutics in oncology and
autoimmune diseases for the global market. Its Commercial Platform
manufactures, markets, and distributes prescription drugs and consumer
health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison
Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Forward-looking statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
involve risks and uncertainties, including statements regarding the
Offering. Actual results may differ materially from those projected or
implied. More information about potential factors that could affect
Chi-Med’s business and financial results is contained in the Form F-1
Registration Statement filed with the SEC. Any forward-looking statement
made by Chi-Med herein, or elsewhere, speaks only as of the date on
which such statement is made. Chi-Med does not intend, and undertakes no
duty, to update any forward-looking statements after the date hereof to
reflect future events or circumstances.

Contacts

Investor Inquiries
Hutchison China MediTech Limited
Christian
Hogg, CEO, +852 2121 8200
or
International Media Inquiries
Citigate
Dewe Rogerson
Anthony Carlisle, +44 7973 611 888 (Mobile)
or
U.S.
Based Media Inquiries

BMC Communications
Brad Miles, +1
917-570-7340
Susan Duffy, +1 917-499-8887
or
Investor
Relations

The Trout Group
Jillian Connell, +1 646-378-2956
or
Citigate
Dewe Rogerson
David Dible, +44 20 7638 9571
+44 7967 566 919
(Mobile)
or
Panmure Gordon (UK) Limited
Richard
Gray/Andrew Potts, +44 20 7886 2500